Many "non-metastatic" cancers have spawned undetectable metastases prior to diagnosis. Eventual outgrowth of these microscopic lesions causes metastatic relapse and death, yet the events that dictate when and how micrometastases convert to overt metastases are largely unknown. We report that macrophage stimulating protein (MSP) and its receptor, Ron, are key mediators in conversion of micrometastases to bona fide metastatic lesions through immune suppression. Genetic deletion of Ron tyrosine kinase activity specifically in the host profoundly blocked metastasis. Our data show that loss of Ron function promotes an effective anti-tumor CD8 + T cell response, which specifically inhibits outgrowth of seeded metastatic colonies. Treatment of mice with a Ron-selective kinase inhibitor prevented outgrowth of lung metastasis, even when administered after micrometastatic colonies had already been established. Our findings indicate that Ron inhibitors may hold potential to specifically prevent outgrowth of micrometastases in cancer patients in the adjuvant setting.
INTRODUCTION
Metastatic tumor growth in secondary organs is the main cause of death from cancer. For example, 20-30% of people diagnosed with Stage II-III breast cancer eventually develop metastatic disease, which typically occurs 3-16 years after the initial diagnosis (1). This clinical "dormancy" period followed by late relapse is also frequently observed in cancers of the prostate, kidney, and thyroid, and in B cell lymphomas and melanoma (2) , making this a critical issue in clinical cancer biology. The long latency between excision of the primary tumor and development of clinically-detectable distant metastasis suggests that micro-metastatic tumor cells are already seeded at other sites throughout the body at the time of diagnosis and surgery, but only "re-awaken" after a period of inactivity or nonproductive growth.
The ability of micrometastatic tumor cells to convert into overt metastases is a key point in disease progression because, once detected, metastatic cancer is essentially incurable. Identifying pathways that can be targeted to prevent metastatic outgrowth is particularly important to understand from a therapeutic perspective, since prevention of very early tumor dissemination may not be clinically feasible. In fact, it has been suggested that "a new frontier" in cancer therapy will be to identify ways to revert or maintain cancers in an occult, minimal residual disease state (2, 3) .
How tumor cells maintain and/or escape clinical dormancy is still largely unknown, but both tumor cell-intrinsic and -extrinsic mechanisms appear to contribute. (TNFα) (4) . Failure to achieve sufficient angiogenesis, even in a proliferating lesion, can also induce dormancy (for review see reference 5). Escape from immune-mediated control has also been demonstrated to contribute to outgrowth of micro-metastases (6) (7) (8) . A recent study of melanoma metastasis demonstrated that dissemination of cancer cells occurs early in tumorigenesis -even before tumors are detectable; however, their outgrowth in metastatic sites was limited by cytostatic CD8 + T lymphocytes (9) . T lymphocytes have also been implicated in late metastatic outgrowth in other models (6) and key cytokines that regulate T cell activity can contribute to maintenance of the dormant state (8) . However, the pathways by which micrometastatic tumor cells suppress T cell responses in order to facilitate outgrowth and give rise to overt metastases are very poorly understood.
CD8
+ cytotoxic T lymphocytes (CTLs) destroy tumor cells using perforin-and granzyme-mediated cell death (10) as well as by secreting TNFα, causing tumor cell apoptosis (11, 12) . To survive, tumor cells evade the immune system through mechanisms such as downregulation of class I major histocompatibility complex (MHC) molecules, production of anti-inflammatory cytokines, and/or recruitment of inflammatory-suppressor cells (13) . However most studies have focused on tumorimmune interactions in established primary tumors rather than in occult metastases.
Identifying and targeting key mechanisms by which tumor cells mediate suppression of
CTLs during metastatic outgrowth holds potential as a strategy to reduce or prevent escape from dormancy, and thereby block progression of metastasis. as matriptase), and the MSP receptor Ron (MST1R, gene product commonly referred to as Ron) become aberrantly overexpressed in around 40%, 45% and 50% of human breast cancers, respectively (14) , and are upregulated in many other cancers as well (15) . We previously reported that overexpression of MSP/matriptase/Ron is a strong, independent, poor prognostic factor for outcome in human breast cancer patients due to metastasis, and that expression of MSP in a mouse model of mammary cancer was sufficient to promote spontaneous metastasis to lung, lymphatics, and bone (14) . However, the mechanisms by which MSP promotes metastasis were not understood.
MSP is constitutively secreted from liver into serum as an inactive protein that is subsequently activated locally on macrophages by matriptase (16) or other extracellular serine proteases (17) in response to infection or injury. The processed MSP binds to Ron, which is selectively expressed on a subset of fully differentiated tissue macrophages, and also at low levels on various epithelial cells (18, 19) . Ron is essential for protection from unregulated inflammation in several models of infection or injury; MSP/Ron signaling is responsible for regulation of several inflammatory mediators such as TNFα, interleukin-12, IFNγ, arginase, and inducible nitric oxide synthase (20) (21) (22) (23) (24) (25) . It is unknown, however, whether the role of MSP/Ron in inflammation also contributes to its function in cancer metastasis.
Here, we utilized both genetic and pharmacological approaches to interrogate the mechanism by which MSP drives metastasis, and determined that MSP facilitates metastasis by suppressing anti-tumor immunity. Blocking MSP/Ron signaling, specifically in the host, selectively prevents conversion of pulmonary micrometastases to metastatic colonies by eliciting an effective CD8 + CTL response. We found that 
RESULTS
Loss of host Ron signaling blocks metastasis. We previously described a highly metastatic transgenic mouse model of breast cancer in which MSP expression drives widespread spontaneous metastasis to clinically relevant sites (PyMT-MSP; (14) ). MSP is a secreted protein, and both the tumor cells and host tissues express endogenous Ron, so the pro-metastatic function of MSP could be attributed to direct effects on tumor cells or to indirect effects on the host tumor microenvironment. To determine whether MSP/Ron promotes metastasis through cell-autonomous or non cell-autonomous mechanisms, we transplanted PyMT-MSP tumor cells or PyMT-pMIG control tumor cells into cleared mammary fat pads of immune-competent syngeneic wild type (WT) mice or syngeneic mice lacking Ron activity through targeted deletion of the intracellular kinase domain (Ron TK-/-; 21)( Figure 1A) . We found that knocking out host Ron function had no significant effect on primary tumor development, growth rates, proliferation, or apoptosis ( Table 1 and Figure S1A -B). However, loss of host Ron activity nearly eliminated spontaneous lung metastasis (p<0.0001; Table 1 and Figure 1B) , suggesting that MSP/Ron functions through the host to promote metastasis. We also noted that, although not statistically significant, control PyMT-MIG tumors were also less metastatic in the Ron TK-/-hosts, suggesting that host Ron may promote metastasis Table 1 ). In fact, MSP is constitutively produced by hepatocytes and present in the serum, where it can then be activated by macrophages in response to tissue injury or remodeling (31, 32) .
Metastasis involves multiple steps: cell detachment from the primary tumor mass, local tissue invasion, entry into the circulation, extravasation into new tissues, colonization, and growth at the distant site (33) . To test whether lack of metastasis in the Ron TK-/-hosts was due to a defect with invasion or intravasation, we analyzed the relative numbers of circulating tumor cells (CTCs) in both groups of mice. CTCs were measured in blood from tumor bearing WT and Ron TK-/-mice by quantifying levels of tumor-specific PyMT mRNA as a surrogate measure. Evidence for CTCs was found in both groups of mice, but we detected no significant difference between WT and Ron TK-/-tumor-bearing hosts ( Figure 1C) . To determine whether host Ron plays a role in the later steps of metastasis, such as metastatic cell extravasation, seeding and/or colonization of lungs, we performed experimental metastasis assays. We injected equal numbers of identical tumor cells into the tail veins of WT or Ron TK-/-mice, and examined the ability of the cells to extravasate and seed the lung (36 hours later) and the ability of the cells to form colonies (5 days later; time points are based on (34)).
Tumor burden was calculated using two different methods, which both consistently supported the same conclusions (see Materials and Methods for details). Both WT and Ron TK-/-hosts were equally competent for extravasation and metastatic seeding ( Figure 1D) . However, Ron TK-/-hosts were defective in supporting the conversion of the seeded micrometastatic cells into metastatic colonies, resulting in less tumor burden in the lungs 5 days after injection ( Figure 1E and Figure S1C ). This effect was sustained; tumor burden in the lungs was still significantly reduced 10 days after injection ( Figure 1F and Figure S1D ), and Ron TK-/-hosts were able to survive about 50% longer than WT hosts before reaching the experimental endpoint of respiratory distress ( Table 1) 
in diminishing MSP-induced phosphorylation of Ron at sub-micromolar concentrations (IC50 <500 nM; Figure S6A) ).
To establish whether BMS-777607/ASLAN002 treatment could reduce metastatic colonization in a manner comparable to that seen in Ron TK-/-hosts, we first tested Ron inhibition in the prophylactic setting. WT mice were treated orally with 50mg/kg BMS-777607/ASLAN002 (or vehicle control) once a day for two weeks (days 1-14).
PyMT-MSP tumor cells were injected into the tail vein on day 3, and on day 14 the lungs were harvested and assessed for tumor colonization. The results showed that prophylactic treatment with BMS-777607/ASLAN002 significantly reduced metastatic Cancer immunotherapy carries strong appeal because the immune response is individualized, it is effective against diverse antigens, and it is potentially able to evolve and retain immunologic memory for long-term control of disease. A major challenge, however, is that by the time tumors are clinically detectable they are already "invisible" Immunohistochemistry. Tissues were processed, sectioned (5μm), and stained using standard procedures. Apoptosis was assessed with TUNEL assays (Roche). Antibodies used for immunohistochemistry were phosphohistone H3 (1:100, Cell Signaling) and CD8 + (1:100, Abcam). The Envision+System HRP detection kit (DAKO) and Vector MOM and HRP kits were used according to manufacturers' instructions.
Lymphocyte isolation and FACS. Splenocytes were isolated by disrupting spleens over a wire mesh, followed by red blood cell (RBC) lysis. Lung lymphocytes were isolated following digestion of lungs in Collagenase IV (Sigma) for 1 hour, followed by Percol (Sigma) separation. Peripheral blood lymphocytes were isolated as previously described (27). Briefly, blood was harvested from WT and Ron TK-/-mice into anti- 
and day 7. On day 10, mice were euthanized and metastatic burden quantified as 
